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There are eleven Member States in the WHO southeast Asia region (Bangladesh, Bhutan, Democratic People’s Republic of Korea,
India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste) of which eight are endemic for rabies. More than
1.4 billion people in the Region are at risk of rabies infection, and approximately 45% of worldwide rabies deaths occur in Asia.
Dog bites account for 96% of human rabies cases. Progress in preventing human rabies through control of the disease in dogs has
been slow due to various factors. Innovative control tools and techniques have been developed and standardized in recent years.
The introduction of cost-eﬀective intradermal rabies vaccination regimens in Asian countries has increased the availability and
aﬀordability of postexposure prophylaxis. Elimination of rabies is not possible without regional and intersectoral cooperation.
Considering the importance of consolidating achievements in rabies control in Member countries, the WHO Regional Oﬃce for
southeast Asia has developed a regional strategy for elimination of human rabies transmitted by dogs in the Region. They have
committed to provide technical leadership, to advocate national health authorities to develop major stakeholder consensus for a
comprehensive rabies elimination programme, and to implement national strategies for elimination of human rabies.
1.Introduction
Rabies is an ancient viral zoonotic disease that is invariably
fatal in humans and mammals. The disease circulates in
two epidemiological cycles: an urban cycle involving main-
tenance of infection in dog populations and a sylvatic cycle
involving wildlife. There is a possibility of spill-over of rabies
virus from dogs to wildlife and vice versa.
Dogs are the most important rabies reservoir. Human
c a s e sh a v ea l s ob e e nr e p o r t e dd u et oe x p o s u r et or a b i d
cats and wildlife. Mongoose (Herpestes spp.), jackals (Canis
aureus), foxes (Vulpes bengalensis)a n dw o l v e s( Canis lupus)
have been incriminated as wildlife reservoirs of rabies in
Bangladesh, India, and Nepal [1]. Recent studies on the
Nepalese ﬁeld rabies virus indicate that it belongs to the
Arctic fox genome [2]. The rabies virus isolated from
a human rabies case was 100% identical to viruses isolated
from two dogs and a mongoose in Nepal [3].
Dog bites are the primary source of human infection in
all rabies endemic countries and account for 96% of rabies
cases in the southeast Asia (SEA) region [4]. Elimination of
human rabies is dependent on elimination of dog rabies.
Countries can be categorized depending on rabies status:
high, medium, and low rabies endemic countries and rabies-
free countries. Maldives, Timor-Leste, and some islands
of India are historically free of rabies. Bangladesh, India,
and Myanmar are high rabies endemic countries. Bhutan,
Nepal, and Sri Lanka are medium rabies endemic countries.
Thailand is moving towards low endemic status, but due
to increasing rabies incidence Indonesia is moving from a
low endemic to a medium rabies endemic country. Rabies is
an emerging disease problem on many islands of Indonesia
which were previously considered rabies-free. Some coun-
tries have a comprehensive rabies control programme but it
is a neglected disease problem in others due to competing
public health priorities and the complex nature of rabies
control activities.
Prevention of rabies in humans depends on a combi-
nation of interventions. These include provision of postex-
posure prophylaxis (PEP) to exposed patients, preexposure2 Advances in Preventive Medicine
immunization of people at high risk of exposure, control
of infection in animal reservoirs, and control of dog
populations [5]. Although rabies is preventable, the high
cost of vaccines, compounded by the lack of education and
awareness about the disease, limits the use of PEP. Recent
studies show that most patients were victims of rabies due
to negligence, ignorance, or the inadequate availability of
primary health care services [4].
Progress in preventing human rabies through control
of the disease in its animal reservoir has been slow. This
has been due to technical, intersectoral, organizational,
and ﬁnancial obstacles. In addition, there has been a
lack of eﬃcient dog rabies control campaigns including
humane canine population management [6]. The success
and sustainability of dog immunization coverage depends
heavily on appropriate management of the dog population.
The eﬀorts towards population management are limited
and disjointed in most countries. Lethal methods of dog
population control have been used in some countries which
have been an expensive option. Attempts to control rabies
through dog culling have not been sustainable or socially
acceptable due to public, religious, and animal welfare
concerns. Furthermore, surgical sterilization of dogs in small
numbers and at irregular intervals does not yield any long-
term beneﬁts in reduction of the population. There are
successful programmes of dog population control in limited
urbanareascoordinatedbyleadingNGOs.However,theyare
location speciﬁc and have not been replicated at rural levels
with community participation.
2. Burden of Disease
Rabiesis a disease of public health and economic importance
in southeast Asia. The annual expenditure due to rabies has
been estimated to be more than US$ 563 million in Asia [7].
This ﬁgure is based on the direct and indirect costs of PEP in
humans and costs incurred from dog rabies control eﬀorts.
Rabies is a disease of poverty, aﬀecting vulnerable pop-
ulations and children. According to available data, children
in the 5–15 year age-group represent about 40% of people
exposed to dog bites in rabies endemic areas [4]. The
majority of bites that occur in children go unrecognized
and unreported and, consequently, exposed children do
not receive the beneﬁt of timely and complete courses
of postexposure prophylactic treatment [8]. Additionally,
paralytic rabies is often misdiagnosed as acute neurological
syndrome. Thus, there is the possibility of a disproportion-
ately high number of young children contracting and dying
of undiagnosed rabies.
More than 1.4 billion people are at potential risk
of rabies infection in the southeast Asia region. Table 1
shows countrywise estimates of human rabies and dog bite
cases.
Each year, 21 000–24 000 people die in the SEA Region
due to rabies. This accounts for approximately 45% of
worldwide human rabies deaths.
Of the estimated 19 million humans bitten by dogs in
the SEA Region, it is estimated that at least 4 million receive
one or more doses of rabies vaccine [9]. In the majority of
countries, the number of patients receiving PEP has steadily
increased over time, particularly in urban areas. This is due
to improvements in awareness, availability, aﬀordability, and
accessibility of safe and eﬀective rabies vaccines particularly
in urban areas. Countries are allocating increasing portions
of health budgets to procurement of modern rabies vaccines
and immunoglobulin to meet the growing demand for PEP.
3. Feasibilityof Eliminationof Human Rabies
The necessary tools and methods for prevention and control
of human and canine rabies are available. The proof of
the feasibility of elimination of dog-mediated rabies has
been demonstrated in countries like Singapore and Malaysia.
It is thought that strict enforcement and policies of dog
registration, vaccination, and dog population management
have made rabies control and eradication eﬀective in these
countries. Malaysia borders Thailand, and the concept of
an immune belt has been developed by dog licensing
and mandatory vaccination of dogs as well as systematic
destruction of unvaccinated dogs in a buﬀer zone to prevent
entry of rabies from the northern border.
Sri Lanka and Thailand have registered a decline in the
number of human rabies deaths through implementation of
a mass dog vaccination campaign, improved accessibility to
PEP, and eﬀective vaccine delivery systems.
Control of rabies through vaccination in the canine
population is fundamental to elimination of human rabies.
Rabies elimination programmes focused mainly on mass
vaccination of dogs are largely justiﬁed by the future savings
of human rabies prevention programmes. The Pan Ameri-
can Health Organization initiated a regionally coordinated
programme for elimination of human rabies transmitted by
dogs in 1983. This was mainly based on mass immunization
of dogs and has led to a 90% reduction in and elimination
of dog rabies from Chile and major urban centers of other
L a t i nA m e r i c a nc o u n t r i e s[ 10]. In Mexico, after ﬁve years
of a nationwide dog vaccination campaign, the number of
human rabies deaths was reduced from 60 per year to less
than 20 [11].
Coordinated mass dog vaccination campaigns will
improve herd immunity levels and prevent potential human
exposure to rabies but strong political commitment and
intensive social mobilization is vital. The active role of
the veterinary authority at the national level for animal
rabies control is crucial and it is their social responsibility
to prevent human rabies through well-planned dog rabies
control programmes. There are increasing numbers of inter-
national partners for dog rabies control and dog population
management in southeast Asia which have been encouraged
since the introduction of World Rabies Day in 2007.
Innovative tools and techniques have been developed
and standardized in recent years which will help to improve
dog vaccination coverage, accessibility, and aﬀordability of
modern rabies vaccine and dog population management. As
an adjunct to parenteral immunization, oral rabies vaccines
(ORVs) have been extensively tested for eﬃcacy and safety
in owned and ownerless dogs. ORV delivery strategies for
dogswhichcannotbereachedbyparenteralvaccinationhaveAdvances in Preventive Medicine 3
Table 1: Distribution per year of human rabies and dog bite cases in countries of the southeast Asia region.
Country Estimated no. of dog
bites
Estimated no. of
human rabies cases
Estimated no. of human
cases per million
population
Source of information
Bangladesh 300,000 2,000–2,500 13 Ministry of Health and Family
Welfare, Bangladesh
Bhutan 5000 <10 3 Ministry of Health, Bhutan
DPR Korea Not available Not available Not available N/A
India 17,400,000 18,000-20,000 18
Assoc. for Prevention and
Control of Rabies in India
(APCRI)
Indonesia 100,000 150–300 1.3 Ministry of Health, Indonesia
M a l d i v e s 000 N / A
Myanmar 600,000 1000 22 Ministry of Health, Myanmar
Nepal 100,000 <100 4 Ministry of Health and
Population, Nepal
Sri Lanka 250,000 <60 3 Public Veterinary Services, Sri
Lanka
Thailand 400,000 <25 0 Ministry of Public Health,
Thailand
Timor Leste 1,000 0 0 Ministry of Health, Timor-Leste
SE ASIA
TOTAL 19,156,000 21,345–23,995
been designed and tested in parts of Asia [12]. However,
the cost of oral rabies vaccine for dog immunization is a
limiting factor. The use of immunocontraception may be
considered, in conjunction with oral and parenteral rabies
vaccination, as a complementary tool to reduce the density
of dog populations and rabies incidence [13].
4. Cost Effectiveness of Intradermalversus
IntramuscularRabiesPEPandRIG
India is the only country in the Region producing various
types of quality rabies tissue-culture vaccines (TCVs). It
is capable of producing 15 million doses of rabies vaccine
annually (Personal communication, Dr. RL Ichhpujani),
which is suﬃcient for whole region. Use of RIG in category
three bites is limited due to the high cost of HRIG
administration. Puriﬁed ERIG is now produced in suﬃcient
quantities in India and Thailand and is safe and aﬀordable to
use.Theavailabilityofhighlyeﬀectivehumanrabiesvaccines
and ERIG within the region is important to prevent possible
human deaths due to exposure to rabid animals.
Cost-eﬀective rabies vaccination schedules were intro-
duced in early 1990s. The WHO Expert Committee in 1991
recommended intradermal application of modern rabies
vaccines for PEP [14]. Multisite intradermal administration
of rabies vaccines reduces the costs of PEP by 60% [15].
The original Thai Red Cross Regimen can be replaced if
two doses of vaccine are given on day 0,3,7, and 28 (“2-2-
2-0-2” regimen) as per the recommendation of the eighth
WHO Expert Consultation [16]. The updated Thai Red
Cross Regimen considerably improves compliance rates as
patients receive the full course within one month. A research
study is ongoing for the administration of a complete PEP
intradermal schedule within the period of one week.
Intradermal rabies vaccination (IDRV) was introduced
a n dw i d e l yu s e di nT h a i l a n di nt h ep a s ta n dh a sb e e n
adapted and promoted in Bangladesh, India, Sri Lanka
and other Asian countries. Today, over 95% of patients
are provided PEP with an IDRV regimen in Sri Lanka
(personal communication, Dr. Omala Wimalaratna). WHO
hasbeenprovidingtechnicalsupporttootherrabiesendemic
countries to introduce the IDRV regimen.
The cost of PEP can be reduced dramatically if the
intramuscular (IM) regimen is replaced in a progressive
manner with the IDRV regimen. The conservative estimate
of costing for human rabies prophylaxis, including vaccine
and serum application for a period of ﬁve years in southeast
Asia region, is presented in Tables 2 and 3. Vaccine wastage
is expected with IDRV due to the short shelf life of the
vaccine after reconstitution and fewer patients at the time of
vaccination. While calculating the cost estimates for IDRV, it
was estimated that 25% vaccine will be wasted.
Table 2 gives cost estimates for the use of IM and ID
PEP regimes. If only the intramuscular (IM) PEP regime
is used over a period of 5 years, the cost estimation is
US $705 million. In contrast, if only the intradermal (ID)
PEP protocol is practiced the cost estimation will be almost
two thirds less at US $226.5 million. This demonstrates the
cost-eﬀectiveness of ID versus IM PEP protocols. Figure 1
illustrates the cost estimate eﬀects of varying the percentage
proportion of ID and IM rabies PEP.
Experience has shown that 25% victims have third
category bites that require rabies serum application. Equine4 Advances in Preventive Medicine
Table 2: Cost estimation of intramuscular (IM) versus intradermal (ID) rabies postexposure prophylaxis (PEP) in the southeast Asia region
over a ﬁve year period.
Activity 100% IM PEP 100% ID PEP
Estimated number of patients taking PEP (millions) 4 4
Volume of TCV required per person for PEP course (milliliters) 5 1
Total volume of TCV required to achieve 100% coverage (+25% wastage for ID) (millions of mLs) 20 5
Cost per millilitre of TCV, incl. syringe + diluent (US$) 7 9
Cost of TCV vaccine per year (million US$) 140 45
Cost of vaccine for ﬁve years (million US$) 700 225
Cost of transportation, storage, etc. (million US$) 5 1.5
Total cost for ﬁve years (million US$) 705 226.5
(TCV: tissue culture vaccine. Vaccine costs calculated at current market rates. Transportation and storage costs estimated as 25% of vaccine volume).
Table 3: Cost comparison of human rabies immunoglobulin (HRIG) versus equine rabies immunoglobulin (ERIG) for postexposure
prophylaxis (PEP) in southeast Asia over a ﬁve-year period.
Activity HRIG ERIG
Estimated number of patients taking PEP (millions) 4 4
No. of dog bite cases requiring RIG application (millions) 1 1
Quantity of RIG required per patient (millilitres) 5 5
Quantity of RIG required per year (millions of mLs) 5 5
Cost of human RIG per mL (million US$) 60 3
Cost of human RIG for year (million US$) 300 15
Cost of transportation, storage etc. (million US$) 2 1.25
Total cost of RIG for ﬁve years (million US$) 1510 81.25
(RIG costs calculated at current market rates. Transportation and storage costs were estimated at 25% of RIG volume).
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Figure 1: Estimated costs of providing varying proportions of
intradermal (ID) versus intramuscular (IM) rabies postexposure
prophylaxis (PEP) to 4 million dog bite patients.
rabiesimmunoglobulin(ERIG)isover18timescheaperthan
human immunoglobulin (HRIG) as shown in Table 3. Using
only HRIG in third-degree bite cases over a ﬁve-year period
will cost approximately US $1.51 billion, whereas using
ERIG over the same period will cost approximately US $57
million.
5. Regional MultisectoralCollaboration
Except for island countries, elimination of rabies is not
possible without regional cooperation. No single country
can maintain rabies-free status unless it is brought under
control in neighbouring countries. Regionally coordinated
eﬀorts are necessary for elimination of human rabies
with consideration of country-speciﬁc needs and socio-
cultural acceptability. WHO launched a regional rabies
control project in the 1980s in Asia and many coun-
tries developed and strengthened national capacity for
rabies surveillance, diagnosis, vaccine production, and dog
population management. This encouraged coordination
and cooperation between human and animal health sec-
tors for rabies prevention and control at the country
level.
Following the ﬁrst WHO recommendation in 1984
to replace nerve-tissue vaccines (NTVs), many developing
countriesofsoutheastAsiahavediscontinuedtheproduction
and use of NTVs for human use [17]. In 2004, the WHO
ExpertConsultationissuedadeﬁnitivestatementtotheeﬀect
that NTVs should be discontinued [16]. As a continuous
eﬀort of WHO and professional organizations, all countries
except Bangladesh and Myanmar have discontinued produc-
tion and use of the Semple type NTV.
Considering the importance of consolidating achieve-
ments in rabies control in Member countries, WHO SEARO
came up with the regional strategy for human rabies
elimination from southeast Asia in 1998. WHO SEARO
organized an intercountry meeting in Colombo, Sri Lanka
in 2005 to review the rabies situation in SEA Region and
to formulate mechanisms for implementation of the strategy
for elimination of rabies [18].Advances in Preventive Medicine 5
It is important that Member States of the Association of
southeastAsianNations(ASEAN)andtheSouthAsianAsso-
ciation for Regional Cooperation (SAARC) have identiﬁed
rabies as a priority public health problem. There is also a
growingconcernandcommitmentforeliminationofhuman
rabies by a number of national governments in the SE Asia
Region. There was a SAARC Rabies Meeting in Colombo in
2003 which was attended by government oﬃcials of Member
countries. The meeting recommended the development of
a SAARC strategy for rabies elimination [19]. The ASEAN
countries adopted the resolution to prevent and control
rabies, with the goal of rabies elimination by year 2020 [20].
The Rabies in Asia Foundation conference held in Hanoi
in September 2009 passed resolutions to take several steps
to reach the goal of human and dog rabies elimination by
2020. The WHO has been requested to reinforce capabilities
to meet the demands from Member States for technical
assistance, technology transfer, and the launching of regional
initiatives for dog rabies control and elimination in Asia in
close collaboration with ASEAN and SAARC [21].
The WHO Strategic Framework for the Elimination of
Human Rabies Transmitted by Dogs in the South East Asia
Region is due for publication in 2011. The document will
provide technical guidance for the regional strategy as well
as national strategies and act as an advocacy tool to develop
consensus among major stakeholders for a comprehensive
rabies elimination programme.
6. Conclusion
The elimination of human rabies transmitted by dogs is an
achievable goal. The initiative has been taken to develop a
unique strategic framework for elimination of human rabies
transmitted by dogs in consideration of the epidemiological
situation, technical feasibility, and the sociocultural context.
The cost beneﬁts of using intradermal rabies vaccines and
equine immunoglobulin for postexposure prophylaxis has
been demonstrated. These techniques must be adopted. The
WHO Strategic Framework will be a vital guide for the
collaborative, intersectoral approach that is necessary for
rabies control. With the adoption of the strategic elements of
this document the huge public health and economic burden
of human rabies can by eliminated in southeast Asia.
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